Take the opportunity to read the pressrelease on the CymaBay study with Seladelpar in the NIF mouse.  Ed Cable, sr. Director of Research at CymaBay Therapeutics, gives his view on why CymaBay chose to work with the NIF mouse, and comments on the positive results. You will find the full pressrelease here.

We are very happy that CymaBay Therapeutics chose to present the convincing data from their study in the NIF mouse. They nicely show that Seladelpar, which is a substance in clinical studies, reduces fibrosis in the NIF mouse in both liver and kidney. You will find the PDF of the poster "Seladelpar reduces established liver [...]

InfiCure Bio attended the EASL NAFLD Summit in September, and presented this poster with up-to-date data on the NIF mouse.

Lena Söderström, Head of board at InfiCureBio, will share her views on listing of companies. Take the opportunity to listen to her experiences!

Inficure Bio will attend the EASLE NAFLD Summit, and present a poster on the NIF mouse. Don't miss the opportunity to take part of the latest updates on how to use the NIF mouse  for preclinical testing of new NASH drugs. Take a look at the poster "The NIF mouse – a unique way to [...]

Present and former members of InfiCure Bio rounded up before summer holidays with a lunch in the sun in central Umeås beautiful park. We now look forward to a relaxing holiday and will return with lots of energy and new ideas in August!

Don't miss the presentation by Sofia Mayans at the virtual 4th Global NASH Congress, April 28 at 12.45, where she will share the latest discoveries on our unique NIF liver model!  

Make sure to book a one-on-one meeting with Dan Holmberg and/or  Sofia Mayans, and take the opportunity to discuss the most recent data on the NIF mouse and learn how the model can help in the development of anti-inflammatory and/or anti-fibrotic drugs.